



*cancers*



an Open Access Journal by MDPI

## Advances in Locally Advanced and Metastatic Kidney Cancer

Guest Editors:

**Dr. Nirmish Singla**

The Brady Urological Institute,  
Johns Hopkins University School  
of Medicine, Baltimore, MD  
21287, USA

**Dr. Yasser Ged**

Department of Medicine, Johns  
Hopkins University School of  
Medicine, Baltimore, MD 21205,  
USA

Deadline for manuscript  
submissions:

**4 July 2024**

### Message from the Guest Editors

Advanced renal cell carcinoma (RCC) exhibits a wide clinical spectrum, ranging from non-metastatic, high-risk or locally advanced tumors, to oligometastatic disease, to more widely disseminated metastatic involvement. In the locally advanced space, increasing interest has turned to administering systemic therapies in the perioperative (neoadjuvant or adjuvant) setting to help reduce recurrence. In the study of oligometastatic disease, new approaches to the locoregional management of metastatic sites, such as stereotactic radiation, have been employed to delay or obviate the need for systemic therapy while minimizing morbidity. In more widely disseminated diseases, novel therapeutic agents and rational combinations continue to emerge for both clear cell and non-clear cell RCC histologies. The role and timing for cytoreductive nephrectomy in metastatic disease continue to evolve, and the ideal setting remains unknown at present.

In this Special Issue, we are seeking high-quality, novel work highlighting advances in locally advanced and metastatic kidney cancer, pertaining to the themes delineated above. We look forward to receiving your contributions.



[mdpi.com/si/131436](https://mdpi.com/si/131436)

# Special Issue



# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI